Stockscreener 앱 받기
0.052
14.75%
-0.009
시간 외 거래:
.05
-0.002
-3.85%
전일 마감가:
$0.061
열려 있는:
$0.075
하루 거래량:
12,102
Relative Volume:
0.34
시가총액:
$N/A
수익:
-
순이익/손실:
$-2.98M
주가수익비율:
-0.2008
EPS:
-0.259
순현금흐름:
$-1.71M
1주 성능:
-30.67%
1개월 성능:
+42.86%
6개월 성능:
-35.00%
1년 성능:
-11.86%
1일 변동 폭
$0.0515
$0.082
1주일 범위
$0.0515
$0.082
52주 변동 폭
$0.0341
$0.1052
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Compare HEPA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.052 | 0 | 0 | -2.98M | -1.71M | -0.259 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-20 | 재개 | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc 주식(HEPA)의 최신 뉴스
Hepion Pharmaceuticals (NASDAQ: HEPA) director discloses holding 1,250,000 shares - Stock Titan
Hepion Pharmaceuticals stock (US4268971032): liver drug developer advances pipeline after reverse sp - AD HOC NEWS
Hepion (OTC: HEPA) posts smaller Q1 loss but warns on going concern - Stock Titan
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Hepion Pharmaceuticals stock (US4268971032): Recent 27.9% surge draws attention - AD HOC NEWS
TradingKey - TradingKey
LoPriore and affiliates disclose 21.46% Hepion (HEPA) ownership stake - Stock Titan
Hepion (NASDAQ: HEPA) seeks shareholder approval for major 8M-share equity plan - Stock Titan
Hepion Pharmaceuticals director Michael J. Purcell buys $50,000 stock By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals director Michael J. Purcell buys $50,000 stock - Investing.com
Director Michael Purcell buys 1.25M Hepion (HEPA) shares - Stock Titan
Hepion Pharmaceuticals Stock (HEPA) Opinions on Executive Separation and ctRNA Licensing - Quiver Quantitative
Hepion director Appajosyula Sireesh buys $50,000 in stock By Investing.com - Investing.com South Africa
Hepion director Appajosyula Sireesh buys $50,000 in stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $50,000 in stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $50,000 in stock By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals: Executive chairman Vincent LoPriore buys $250,000 in stock - Investing.com Australia
Insider-linked funds buy 6.25M Hepion (HEPA) shares at $0.04 - Stock Titan
Director at Hepion (HEPA) makes 1,250,000-share open-market stock purchase - Stock Titan
Hepion (NASDAQ: HEPA) interim CEO linked to 1.25M-share open-market buy - Stock Titan
Hepion Pharmaceuticals Announces Private Placement Financing Agreement - TipRanks
Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04 - TradingView
Hepion Pharmaceuticals (HEPA) sells 17.5M shares in $700K private deal - Stock Titan
Hepion Pharmaceuticals, Inc. announced that it has received $0.7 million in funding - marketscreener.com
Hepion Pharmaceuticals enters separation agreement with former CEO Dr. Kaouthar Lbiati By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals enters separation agreement with former CEO Dr. Kaouthar Lbiati - Investing.com Australia
Hepion Finalizes CEO Separation Agreement Amid Leadership Transition - TipRanks
Hepion Pharmaceuticals (HEPA) CEO and director step down with severance deal - Stock Titan
Tech Rally: Is Hepion Pharmaceuticals Inc affected by consumer sentiment2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn
Analyst Calls: Does SKLZ stock benefit from AI growth2026 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn
MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast - Defense World
Hepion Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript - GuruFocus
HEPA (Hepion Pharmaceuticals) Non Operating Income : $-4.49 Mil (TTM As of Dec. 2025) - GuruFocus
HEPA (Hepion Pharmaceuticals) 3-Year Share Buyback Ratio : -434.70% (As of Dec. 2025) - GuruFocus
Value Recap: What are analysts price targets for Hepion Pharmaceuticals Inc2026 Pullback Review & Stock Timing and Entry Methods - baoquankhu1.vn
Is Hepion Pharmaceuticals Inc stock good for income investors2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hepion Pharmaceuticals Inc (HEPA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
S P Trends: Can Hepion Pharmaceuticals Inc be the next market leader2026 Setups & Verified Entry Point Detection - baoquankhu1.vn
Hepion Pharmaceuticals CEO Resigns and Interim CEO Appointed – Official SEC Filing March 2026 - Minichart
Hepion Pharmaceuticals (NASDAQ: HEPA) CEO Gary Stetz submits Form 3 - Stock Titan
Hepion Pharmaceuticals (OTC: HEPA) CEO exits as board installs new leaders - stocktitan.net
Bearish Setup: How sensitive is Hepion Pharmaceuticals Inc to inflationTrade Exit Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Hepion Pharmaceuticals Stock (ISIN: US4268971032) Faces Uncertainty Amid Pipeline Delays and Biotech - AD HOC NEWS
Hepion (HEPA) exits liver drug program, pivots to diagnostics as cash window narrows - Stock Titan
HEPA: Net loss narrowed to $8.3M in 2025 as operations shifted to diagnostics, but no revenue was generated - TradingView
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Hepion Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
HEPA (Hepion Pharmaceuticals) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Gap Down: Should I buy Hepion Pharmaceuticals Inc. stock now2026 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Hepion Expands Liver Cancer Liquid Biopsy Theranostics Portfolio - TipRanks
Hepion Pharmaceuticals (HEPA) Enhances Early Cancer Detection wi - GuruFocus
Hepion Pharmaceuticals Inc (HEPA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):